Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Recurrence × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Leukemia 3 Vomiting 2 Stomach Neoplasms 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Motor Activity 2 Ventilator-Induced Lung Injury 1 Urologic Neoplasms 1 Urogenital Neoplasms 1 Substance-Related Disorders 1 Solid Tumors 1 Recurrence 1 Postoperative Complications 1 Pancreatic Neoplasms 1 Opioid-Related Disorders 1 Opioid-Induced Constipation 1 Neurofibromatosis 1 1 Neoplasms 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Lymphoma 1 Lung Neoplasms 1 Low Anterior Resection Syndrome 1 Kidney Neoplasms 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 151 Dexamethasone 139 Rituximab 82 fludarabine 78 Cytarabine 69 Lenalidomide 68 fludarabine phosphate 62 Gemcitabine 62 Bortezomib 62 venetoclax 54 Etoposide 53 pembrolizumab 51 Paclitaxel 48 pomalidomide 47 Cisplatin 47 Carboplatin 47 Peripheral Blood Stem Cell Transplantation 46 Filgrastim 40 Radiotherapy 39 Calcium Dobesilate 36 Busulfan 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 29 Vincristine 28 Temozolomide 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡